Company intelligence / Profile preview
SignalRx Pharmaceuticals
San Diego, CA, USsignalrx.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Phase 1
01
Overview
Focus on multi-target small molecules, emphasis on synergistic pathway inhibition, active collaborations for drug delivery systems. Notable candidate SFX2523 inhaled formulation in development for lung pathologies. Preclinical data shows broad anticancer activity across multiple cancer types. Ongoing research on BRD4-based therapeutics and DNA methyltransferase inhibitors.
- Therapeutic areas
- OncologyPulmonologyInfectious Diseases
- Modalities
- Small molecule drug
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Crystec PharmaADYA Consulting
Beyond the preview
Go deeper on SignalRx Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SignalRx Pharmaceuticals.